bluuebunny/crossref_metadata_2025_split huggingface dataset:
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
Authors: Hasegawa Kosei , Takahashi Shunji , Ushijima Kimio , Okadome Masao , Yonemori Kan , Yokota Harushige , Vergote Ignace , Monk Bradley J. , Tewari Krishnansu S. , Fujiwara Keiichi , Li Jingjin , Jamil Shaheda , Paccaly Anne , Takehara Kazuhiro , Usami Tomoka , Aoki Yoichi , Suzuki Nao , Kobayashi Yoichi , Yoshida Yoshio , Watari Hidemichi , Seebach Frank , Lowy Israel , Mathias Melissa , Fury Matthew G. , Oaknin Ana 
Published: September 2024

AbstractBackgroundIn the phase 3 EMPOWER‐Cervical 1/GOG‐3016/ENGOT‐cx9 study, cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first‐line platinum‐based chemotherapy. We present a post hoc subgroup analysis of patients enrolled in Japan.MethodsPatients were enrolled regardless of programmed cell death‐ligand 1 status and randomized 1:1 to cemiplimab 350 mg intravenously every 3 weeks or investigator's choice single‐agent chemotherapy for up to 96 weeks. Primary endpoint was OS. Key secondary endpoints were progression‐free survival (PFS) and objective response rate (ORR).ResultsOverall, 608 patients were randomized, of whom 56 (9.2%) were in Japan (cemiplimab, n = 29; chemotherapy, n = 27). The median (range) duration of follow‐up was 13.6 (6.0–25.3) versus 18.2 (6.0–38.2) months for patients in Japan and for the overall population, respectively. Median OS (95% confidence interval [CI]) was 8.4 (7.0‐not evaluable) and 9.4 (5.4–14.9) months for cemiplimab versus chemotherapy (hazard ratio [HR]: 0.86; 95% CI: 0.43–1.68). Median PFS (95% CI) was 4.0 (1.4–8.2) versus 3.7 (1.8–4.2) months with cemiplimab and chemotherapy (HR: 0.90; 95% CI: 0.50–1.61), respectively. ORR was 17.2% for cemiplimab and 7.4% for chemotherapy (odds ratio, 2.47; 95% CI, 0.44–13.99). Incidence of treatment‐emergent adverse events at any grade was 79.3% for cemiplimab and 100% for chemotherapy. Grade ≥3 adverse events were 37.9% versus 66.7% with cemiplimab and chemotherapy, respectively.DiscussionWhile acknowledging limitations inherent to a small subgroup analysis, the HR of 0.86 observed in Japanese patients suggests an emerging survival benefit despite a 4.6‐month shorter median duration of follow‐up versus the overall study population.
The Industrial Application Potential of Sugar Beet Pulp Derived Monosaccharides d‐Galacturonic Acid and l‐Arabinose.
Authors: Jansen Laura M. , Hendriks Veronique C. A. , Bentlage Herman , Ranoux Adeline , Raaijmakers Harry W. C. , Boltje Thomas J. 
Published: September 2024

AbstractThis review provides a perspective on the industrial application potential of sugar beet pulp (SBP) derived monosaccharides. The broad application of these monosaccharides could contribute to bio‐based alternatives and sustainable practices, essential for the transition towards a more circular economy. This review focuses on the utilization and application of two SBP monosaccharides, d‐galacturonic acid (d‐GalA) and l‐arabinose (l‐Ara), derived from pectin and hemicellulose. These polysaccharides are major components of sugar beet pulp, an important side stream of sucrose production. d‐GalA and l‐Ara are therefore abundant in biomass and offer unique molecular structures amenable to selective chemical or enzymatic modifications. We review their application in various industrial applications such as the development and production of bioactive compounds, home and personal care products, and other industries.
The “Cuttering (Cutting‐Dottering Balloon) Technique” for treatment of flow‐limiting coronary intramural hematoma
Authors: Gasparini Gabriele Luigi , Maurina Matteo , Regazzoli Damiano , Canova Paolo , Leone Pier Pasquale , Mangieri Antonio , Reimers Bernhard 
Published: September 2024

AbstractBackgroundCoronary artery dissections are caused by a tear in the vessel endothelium, resulting in blood extravasation into the subintimal space, with subsequent intramural hematoma (IMH). One potential technique to deal with this complication is the use of cutting balloons, however, a significant number of cases experienced distal propagation of the hematoma. We describe a novel technique that enhances the possibility of creating intimal tears between the false and true lumen, aiding in hematoma drainage and restoring distal coronary flow.MethodsWe conducted a retrospective analysis of seven consecutive patients who underwent percutaneous coronary intervention complicated by flow‐limiting intramural hematomas. All patients were treated using the “Cuttering Technique,” based on the operators’ preference. Procedural success was defined as achieving a distal thrombolysis in myocardial infarction 3 (TIMI 3) flow.ResultsIn five out of seven patients treated with “Cuttering Technique” we observed a complete restoration of TIMI 3 flow into the dissected segment.ConclusionsOur cases show the effectiveness of the “Cuttering Technique” as a viable approach for managing IMHs. This technique enhances the possibility of creating intimal tears between the false and true lumens, aiding in hematoma drainage and restoring distal coronary flow.
The Polish political scene vis‐à‐vis acts of mass anti‐Semitic violence in the interwar period: Reconnaissance (1918–1939)
Authors: Krzywiec Grzegorz 
Published: September 2024

ABSTRACTThe article provides a qualitative analysis of the political discourse in highly polarized political environment and the role of political divisions in shaping the collective violence. The paper will summarize attitudes toward pogrom violence of key political parties in pre WW2 Poland.
Wearable dual‐band dual‐polarized screen‐printed fabric antenna enabled with electromagnetic bandgap structure for ISM and WLAN communications
Authors: Somasundaram Arulmurugan , TR SureshKumar , Sidén Johan , Alex Zachariah C 
Published: September 2024

SummaryA wearable dual‐band dual‐polarized fabric antenna is screen printed on a cotton polyester substrate to operate at the industrial scientific and medical band at 2.45 GHz and wireless local area network at 5.2 GHz. A rectangular slot with a pair of L‐shaped branches are used to excite dual bands. The rectangular slot is used to achieve lower band resonance at 2.45 GHz with linear polarization, and an L‐shaped branch with a stub is used to obtain the circular polarization at 5.2 GHz. A 3 × 3 electromagnetic bandgap (EBG) structure is enabled behind the antenna to minimize the back radiation and specific absorption rate (SAR). The antenna provides a measured impedance bandwidth (BW) of 25% from 2.1 to 2.7 GHz (600 MHz), and 18% from 4.5 to 5.7 GHz (1.2 GHz), respectively. The antenna also has a 3‐dB axial ratio BW of 15% from 4.6 to 5.35 GHz (750 MHz). The antenna exhibits a measured gain of 5.1 dB at 5.2 GHz and 6.4 dB at 2.45 GHz. The SAR is validated by using a CST (computer simulation technology) voxel human body model and found to be 0.0949 and 0.127 W/kg for 1 g tissue at 5.2 and 2.45 GHz, respectively. The dimension of the proposed EBG integrated antenna is (0.52 λ × 0.52 λ × 0.07 λ). The antenna and EBG structure are screen printed with silver conductive ink, which provides good conductivity, conformability, comfort, wearability, and being lightweight.
Semaglutide “Ozempic” Face and Implications in Cosmetic Dermatology
Authors: Montecinos Karen , Kania Barbara , Goldberg David J. 
Published: September 2024

ABSTRACTBackgroundSemaglutide, a glucagon‐like peptide‐1 receptor agonist, has been utilized for the treatment of type 2 diabetes. Recently, it has gained popularity for its ability to aid in weight loss. However, rapid weight loss induced by semaglutide has been shown to lead to noticeable facial volume loss and the appearance of a prematurely aged face referred to as “Ozempic face.” As this term gains more popularity and increasingly more nondiabetic patients seek rapid weight loss options, there is growing concern among patients and healthcare providers regarding using semaglutide for weight loss as it may have a negative impact on facial esthetics.ObjectiveThe purpose of this paper is to investigate the semaglutide face phenomenon associated with GLP‐1 agonist use for the treatment of obesity.MethodsA comprehensive search on PubMed was conducted to identify the available information related to semaglutide regarding Ozempic face. The search was conducted using a combination of keywords, including “semaglutide,” “semaglutide face,” and “Ozempic face.”Results“Semaglutide face” is recognized as having similar characteristics to a naturally occurring aging face. However, the characteristics of an Ozempic face occur in people much younger than what is seen with the natural aging process. While some believe that this phenomenon is attributed to acute weight loss at a faster rate than normal, many physicians argue that the semaglutide face phenomenon is more likely to occur with the amount of weight lost overall rather than whether that individual used a semaglutide medication to achieve the weight reduction or not. Overall, the semaglutide face phenomenon is characterized by elastin and collagen loss, fat and muscle volume loss, and excessive sagging skin.ConclusionsThe semaglutide face phenomenon highlights the esthetic implications of using semaglutide for the promotion of accelerated weight loss. While this term is not medically recognized, the hollow or sunken look following rapid weight loss sheds light on the effect of semaglutide in facial fat redistribution and volume loss. The metabolic changes induced by GLP‐1 agonists can impact adipose and muscle tissue, which can lead to changes in facial contour and overall appearance. While semaglutide‐induced facial changes may resemble signs of premature aging, they are distinct in their rapid onset and association with significant weight loss. Individuals experiencing semaglutide face have treatment options available depending on their own treatment goals.
Uses of Dupilumab in Dermatology: A Systematic Review of the Randomized Controlled Trials
Authors: Alenazy Asmaa Enad , Alanazi Yasmeen Mohammed , Alanazi Sumayyah Inad , Alrohaimi Nehal Hassan 
Published: September 2024

ABSTRACTBackgroundDupilumab has shown promise as a therapeutic option in dermatology, particularly in conditions like atopic dermatitis (AD), prurigo nodularis, and alopecia areata. This systematic review aimed to analyze the efficacy, safety, and benefits of dupilumab based on findings from placebo‐controlled trials in dermatological conditions.Study AimThe objective was to systematically review placebo‐controlled trials evaluating dupilumab in dermatological conditions and analyze the outcomes related to efficacy, safety, and patient‐reported outcomes (PROs).MethodologyA comprehensive search was conducted in electronic databases (PubMed/MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science) using keywords related to “dupilumab,” “dermatology,” “randomized controlled trial,” and “placebo.” Inclusion criteria encompassed randomized controlled trials comparing dupilumab against placebo, reporting relevant outcomes, and excluding non‐randomized studies or those with interventions other than dupilumab.ResultsThe review included nine placebo‐controlled trials with a total sample size of 6797 participants. Dupilumab demonstrated significant improvements in clinical severity, PROs, anxiety/depression symptoms, and health‐related quality of life (HRQoL) compared to placebo in patients with moderate‐to‐severe AD. In prurigo nodularis, dupilumab showed significant improvements in pruritus and nodule reduction compared to placebo. Promising results were observed in alopecia areata, particularly in patients with high baseline IgE levels, with improvements in SALT scores and hair regrowth. PROs such as itch, sleep, mental health, and overall quality of life were improved with dupilumab, especially with the 300 mg dose regimens.ConclusionThe findings from placebo‐controlled trials support the efficacy and safety of dupilumab in dermatological conditions, including AD, prurigo nodularis, and alopecia areata. Dupilumab appears to be a valuable therapeutic option, with potential benefits in improving clinical outcomes and PROs. Further research is warranted to explore its efficacy in other conditions and optimize dosing regimens for personalized treatment approaches.
Knockout of rbm24a and rbm24b genes in zebrafish impairs skeletal and cardiac muscle integrity and function during development
Authors: Saquet Audrey , Ying Ziwei , Shi De‐Li , Grifone Raphaëlle 
Published: September 2024

AbstractBackgoundSkeletal and cardiac muscles are contractile tissues whose development and function are dependent on genetic programs that must be precisely orchestrated in time and space. In addition to transcription factors, RNA‐binding proteins tightly regulate gene expression by controlling the fate of RNA transcripts, thus specific proteins levels within the cell. Rbm24 has been identified as a key player of myogenesis and cardiomyogenesis in several vertebrates, by controlling various aspects of post‐transcriptional regulation, including pre‐mRNA alternative splicing and mRNA stabilization. In zebrafish, knockdown of rbm24a or rbm24b also causes skeletal and cardiac muscle phenotypes, but how their combined loss affects muscle integrity and function remains elusive.ResultsBy genome editing, we have generated rbm24a and rbm24b single mutants as well as double mutants. Structural analyses indicate that homozygous rbm24a and rbm24b double mutants exhibit severe somitic muscle and cardiac phenotypes, although rbm24b single mutants are obviously normal. We further show that the loss of rbm24a and rbm24b disrupts sarcomere organization, impairing functional contractility and motility of skeletal and cardiac muscles.ConclusionThe rbm24 mutant zebrafish represents a new genetic tool for in‐depth studies of Rbm24‐mediated post‐transcriptional regulation of skeletal and cardiac muscle development, disease and regeneration.
User involvement in the design and development of medical devices in epilepsy: A systematic review
Authors: Ferreira João , Peixoto Ricardo , Lopes Lígia , Beniczky Sándor , Ryvlin Philippe , Conde Carlos , Claro João 
Published: September 2024

AbstractObjectiveThis systematic review aims to describe the involvement of persons with epilepsy (PWE), healthcare professionals (HP) and caregivers (CG) in the design and development of medical devices is epilepsy.MethodsA systematic review was conducted, adhering to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Eligibility criteria included peer‐reviewed research focusing on medical devices for epilepsy management, involving users (PWE, CG, and HP) during the MDD process. Searches were performed on PubMed, Web of Science, and Scopus, and a total of 55 relevant articles were identified and reviewed.ResultsFrom 1999 to 2023, there was a gradual increase in the number of publications related to user involvement in epilepsy medical device development (MDD), highlighting the growing interest in this field. The medical devices involved in these studies encompassed a range of seizure detection tools, healthcare information systems, vagus nerve stimulation (VNS) and electroencephalogram (EEG) technologies reflecting the emphasis on seizure detection, prediction, and prevention. PWE and CG were the primary users involved, underscoring the importance of their perspectives. Surveys, usability testing, interviews, and focus groups were the methods used for capturing user perspectives. User involvement occurs in four out of the five stages of MDD, with production being the exception.SignificanceUser involvement in the MDD process for epilepsy management is an emerging area of interest holding a significant promise for improving device quality and patient outcomes. This review highlights the need for broader and more effective user involvement, as it currently lags in the development of commercially available medical devices for epilepsy management. Future research should explore the benefits and barriers of user involvement to enhance medical device technologies for epilepsy.Plain Language SummaryThis review covers studies that have involved users in the development process of medical devices for epilepsy. The studies reported here have focused on getting input from people with epilepsy, their caregivers, and healthcare providers. These devices include tools for detecting seizures, stimulating nerves, and tracking brain activity. Most user feedback was gathered through surveys, usability tests, interviews, and focus groups. Users were involved in nearly every stage of device development except production. The review highlights that involving users can improve device quality and patient outcomes, but more effective involvement is needed in commercial device development. Future research should focus on the benefits and challenges of user involvement.
RUNX1::MIR99AHG Chimera in Acute Myeloid Leukemia
Authors: Andersen Kristin , Tjønnfjord Geir E. , Ramslien L. Frode , Panagopoulos Ioannis 
Published: September 2024

ABSTRACTRUNX1 fuses with over 70 different partner genes in hematological neoplasms. While common RUNX1 chimeras have been extensively studied and their prognosis is well established, our current understanding of less common RUNX1 chimeras is limited. Here, we present a case of acute myeloid leukemia (AML) with a rare RUNX1 chimera. Bone marrow cells obtained at diagnosis from a 71‐year‐old patient diagnosed with AML‐M5 were studied using G‐banding, fluorescence in situ hybridization, array comparative genomic hybridization, RNA sequencing, PCR, and Sanger sequencing. Combined findings from the abovementioned assays suggested three cytogenetic clones: one with a normal karyotype, one with inv(21)(q21q22), and one with two inv(21)(q21q22). The molecular analysis revealed the fusion of RUNX1 with MIR99AHG (at 21q21.1), further supporting the presence of an inv(21)(q21q22). The present case is the third reported AML harboring a RUNX1::MIR99AHG chimera. Similar to the two previously described AML patients, our case also had an FLT3 aberration.
Petrogenesis of Mafic Dykes in the Beishan Orogen and Its Implications for Subduction of Liuyuan Ocean: Constraints From Geochemistry and Sr‐Nd‐Hf Isotopes
Authors: Peng Ren , Zhang Guishan , Zhao Zhi‐Qi 
Published: September 2024

ABSTRACTSubduction zones are the primary locations of material exchange between the crust and mantle, and thus, arc igneous rocks are extensively examined to explore crust–mantle interactions during oceanic subduction. In this study, the Sr‐Nd‐Hf isotopic compositions and elemental characteristics of the Yinwaxia mafic dykes from the Shibanshan–Huaniushan arc in the southern Beishan Orogen were investigated to determine their petrogenesis and explore crust–mantle interactions during the subduction of the Liuyuan Ocean. The dykes were subdivided into two groups based on their geochemical composition and spatial distribution. Group I dykes in the northern Yinwaxia area possess depleted light rare earth elements and slightly enriched large‐ion lithophile elements, indicated by relatively high ratios of Rb/Nb (1.4–82), Ba/Nb (6–408), and Cs/Nb (0.13–2.74), and low ratios of Th/Yb (0.03–0.39), Th/Nb (0.10–0.83), and (La/Yb)
N
(0.33–1.36). Further isotopic composition study revealed that low values of (87Sr/86Sr)
i
(0.7028–0.7052), and high values of ε
Nd(t) (4.9–9.1) and ε
Hf(t) (13.2–24.0), which suggests that the mantle source of Group I dykes was metasomatized by aqueous fluids. In Group II dykes located in the southern Yinwaxia area, enrichment of light rare‐earth elements and large‐ion lithophile elements was observed, featuring lower ratios of Rb/Nb (0.5–16.7), Ba/Nb (13–51), and Cs/Nb (0.15–1.56), but higher ratios of Th/Yb (0.25–2.64), Th/Nb (0.19–1.49), and (La/Yb)
N
(1.09–2.98) compared to Group I. Furthermore, Group II dykes exhibited higher values of (87Sr/86Sr)
i
(0.7051–0.7077) and lower ε
Nd(t) (−1.7 to +3.8) and ε
Hf(t) (3.7–9.4) isotopic compositions, which suggests that the slab fluids involved in their mantle source were dominated by sediment‐derived melts. The difference between the mafic dykes from Groups I and II suggests the addition of steadily increasing amounts of sediment‐derived melt in their mantle source; moreover, the increased (La/Yb)
N
ratio and decreased ε
Nd(t) with increasing distance from the Liuyuan mélange are records of the spatial evolution of the composition of the slab fluids during the oceanic subduction of Liuyuan Ocean in the early Permian.
Activating mutations remodel the chromatin accessibility landscape to drive distinct regulatory networks in KMT2A‐rearranged acute leukemia
Authors: Zhang Qirui , Falqués‐Costa Ton , Pilheden Mattias , Sturesson Helena , Ovlund Tina , Rissler Vendela , Castor Anders , Marquart Hanne V. H. , Lausen Birgitte , Fioretos Thoas , Hyrenius‐Wittsten Axel , Hagström‐Andersson Anna K. 
Published: September 2024

AbstractActivating FLT3 and RAS mutations commonly occur in leukemia with KMT2A‐gene rearrangements (KMT2A‐r). However, how these mutations cooperate with the KMT2A‐r to remodel the epigenetic landscape is unknown. Using a retroviral acute myeloid leukemia (AML) mouse model driven by KMT2A::MLLT3, we show that FLT3ITD, FLT3N676K, and NRASG12D remodeled the chromatin accessibility landscape and associated transcriptional networks. Although the activating mutations shared a common core of chromatin changes, each mutation exhibits unique profiles with most opened peaks associating with enhancers in intronic or intergenic regions. Specifically, FLT3N676K and NRASG12D rewired similar chromatin and transcriptional networks, distinct from those mediated by FLT3ITD. Motif analysis uncovered a role for the AP‐1 family of transcription factors in KMT2A::MLLT3 leukemia with FLT3N676K and NRASG12D, whereas Runx1 and Stat5a/Stat5b were active in the presence of FLT3ITD. Furthermore, transcriptional programs linked to immune cell regulation were activated in KMT2A‐r AML expressing NRASG12D or FLT3N676K, and the expression of NKG2D‐ligands on KMT2A‐r cells rendered them sensitive to CAR T cell‐mediated killing. Human KMT2A‐r AML cells could be pharmacologically sensitized to NKG2D‐CAR T cells by treatment with the histone deacetylase inhibitor LBH589 (panobinostat) which caused upregulation of NKG2D‐ligand levels. Co‐treatment with LBH589 and NKG2D‐CAR T cells enabled robust AML cell killing, and the strongest effect was observed for cells expressing NRASG12D. Finally, the results were validated and extended to acute leukemia in infancy. Combined, activating mutations induced mutation‐specific changes in the epigenetic landscape, leading to changes in transcriptional programs orchestrated by specific transcription factor networks.
Divergent Synthesis of Trifluoromethyl Ketones via Photoredox Activation of Halotrifluoroacetones
Authors: Giri Rahul , Kissling Mathias , Zhilin Egor , Fernandes Anthony J. , Ordan Quentin E. L. , Katayev Dmitry 
Published: September 2024

AbstractFluorine's high electronegativity, lipophilicity, and metabolic stability make it a valuable element for drug design and development. Consequently, significant synthetic efforts have focused on introducing fluorine and fluorinated motifs into organic molecules, with the synthesis of trifluoromethyl ketones (TFMKs) recently attracting considerable attention. Building on our ongoing research on radical organofluorine chemistry, we present herein the divergent synthesis of trifluoromethyl ketones directly from olefins using readily available chloro‐ and bromotrifluoroacetone as synthetic precursors of the trifluoroacetonyl radical under photoredox catalysis. Mechanistic studies revealed that the divergence is attained through radical polar crossover (RPC) and hydrogen atom transfer (HAT) mechanisms.